The Longevity Reality Radar
46 approaches, rated by evidence.

CRISPR-Cas12a2 for p53 cancers

RNA-triggered chromatin shredding (CRISPR-Cas12a2) for p53-mutant cancers. Cancer. Reviewed Jul 2026.

Selectively killed p53-mutant cells in the lab, and nobody yet knows how to deliver it to every tumour cell in a living body.

Stage
Preclinical, lab only
Rung: Experimental. Animal, lab or theoretical. Years away, if ever.
Evidence grade
D
lab only
Animal or lab only, single pilot, or case reports. How grades work.

What it is

A CRISPR enzyme (Cas12a2) from Jennifer Doudna's lab programmed to sense the mutant p53 transcript inside a cell and, only when it detects that exact RNA, shred the cell's chromatin to trigger its death. The cancer mutation itself becomes the kill switch — no druggable protein pocket needed, healthy cells spared.

The evidence

Published in Nature (8 June 2026, Zeng & Doudna, UC Berkeley / Innovative Genomics Institute): selective elimination of TP53-mutant cells in the lab. The unsolved half — stated by the researchers themselves — is delivering the system into every tumor cell in a living body, the same wall where prior CRISPR cancer approaches have stalled. Real advance, real wall.

What you can do today

Not available for this use, and years away if it arrives at all. Anything sold today with this claim is not backed by human evidence for it.

Sources

Change history

No ladder moves or corrections logged for this entry yet. Changes are dated on the change log.

Related

More in Cancer

All 9 in Cancer.

  • Pelareorep for pancreatic cancerGrade C, response rates only. Phase 3, pancreatic cancer.Response rates in later-line settings beat the approved comparator, but that is not randomised survival data and the Phase 3 has not reported.
  • mRNA-4157 melanoma vaccineGrade B, Phase 3 unpublished. Phase 3, positive topline.Phase 3 beat Keytruda alone on recurrence, but only a press release exists, hazard ratios are unpublished and overall survival is immature.
  • mRNA vaccine for pancreatic cancerGrade C, small early trial. Phase 1/2, pancreatic cancer.Nearly 90% of patients whose immune system responded were alive up to six years later in a small early trial, and randomised survival results have not been reported.
  • CAR-T for solid tumoursGrade C, early responses. Phase 1/2.Encouraging early responses in gastric and some childhood tumours, but it is not curative for most solid cancers.
  • Creatine and cancer immunotherapyGrade D, mouse study. Preclinical.Improved anti-tumour immune signalling in mouse melanoma and has not been tested in people with cancer.
  • Ivermectin for cancerGrade D, case reports. Preclinical, case reports.Lab and mouse data plus uncontrolled case reports, no controlled human trial, and self-treating melanoma risks a fatal delay.